{"id":573066,"date":"2025-09-04T00:00:00","date_gmt":"2025-09-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0052-biopharma-hodgkins-lymphoma-epidemiology-mature-markets\/"},"modified":"2026-03-31T10:25:05","modified_gmt":"2026-03-31T10:25:05","slug":"epidon0052-biopharma-hodgkins-lymphoma-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0052-biopharma-hodgkins-lymphoma-epidemiology-mature-markets\/","title":{"rendered":"Hodgkin&#8217;s Lymphoma &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of Hodgkin\u2019s lymphoma (<abbr title=\"Hodgkin\u2019s lymphoma\">HL<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the <abbr data-abbreviation-entity=\"6799\" title=\"diagnosed\">Dx<\/abbr> incidence and <abbr data-abbreviation-entity=\"6799\" title=\"diagnosed\">Dx<\/abbr> prevalence of <abbr title=\"Hodgkin\u2019s lymphoma\">HL<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities for first line of therapy are also forecast across the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology&#8217;s <abbr title=\"Hodgkin\u2019s lymphoma\">HL<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr title=\"Hodgkin\u2019s lymphoma\">HL<\/abbr>, how many in each of the major mature pharmaceutical markets are eligible for first line of treatment?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"Hodgkin\u2019s lymphoma\">HL<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr data-abbreviation-entity=\"10739\" title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 29 <abbr title=\"Hodgkin\u2019s lymphoma\">HL<\/abbr> populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of <abbr title=\"Hodgkin\u2019s lymphoma\">HL<\/abbr>.<\/li>\n<li>Diagnosed incident cases of classical Hodgkin\u2019s lymphoma (<abbr title=\"classical Hodgkin\u2019s lymphoma\">CHL<\/abbr>).<\/li>\n<li>Diagnosed incident cases of nodular lymphocyte-predominant Hodgkin\u2019s lymphoma (<abbr title=\"nodular lymphocyte-predominant Hodgkin\u2019s lymphoma\">NLPHL<\/abbr>).<\/li>\n<li>Diagnosed incident cases of <abbr title=\"classical Hodgkin\u2019s lymphoma\">CHL<\/abbr> by histology subtype.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"classical Hodgkin\u2019s lymphoma\">CHL<\/abbr> by stage distribution<\/li>\n<li>Diagnosed incident cases of <abbr title=\"nodular lymphocyte-predominant Hodgkin\u2019s lymphoma\">NLPHL<\/abbr> by stage distribution<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"classical Hodgkin\u2019s lymphoma\">CHL<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"nodular lymphocyte-predominant Hodgkin\u2019s lymphoma\">NLPHL<\/abbr>.<\/li>\n<li>Drug-treatable prevalent cases of <abbr title=\"classical Hodgkin\u2019s lymphoma\">CHL<\/abbr>.<\/li>\n<li>Drug-treatable prevalent cases of <abbr title=\"nodular lymphocyte-predominant Hodgkin\u2019s lymphoma\">NLPHL<\/abbr>.<\/li>\n<\/ul>\n<p>\u2026 and more (details available on request).<\/p>\n","protected":false},"template":"","class_list":["post-573066","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573066\/revisions"}],"predecessor-version":[{"id":573268,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573066\/revisions\/573268"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=573066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}